SynthesisBMC geriatrics2025
Efficacy and safety of CT-guided 125I particle implantation for the treatment of elderly lung cancer: a system evaluation and meta-analysis.
Synthesis in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Seven-year follow-up demonstrating sustained survival followingOncology letters · 2026Article
- Combined Use of RadioactiveCancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo systematically evaluate the efficacy and safety of 125I particle implantation in the treatment of elderly lung cancer.
methodsBoth randomized and non-randomized controlled studies on CT-guided 125I particle implantation therapy for the treatment of elderly lung cancer patients were retrieved from databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, Wanfang Data, VIP, and SinoMed from inception to October 31, 2022. Two researchers screened the retrieved studies, extracted data, and evaluated the study quality independently. Then, meta-analysis was conducted using RevMan5.3 and Stata15 software.
resultsA total of 15 studies were included, involving 886 subjects. The meta-analysis results showed that compared with the control group, the 125I particle implantation group had a higher objective response rate [RR = 1.71, 95% CI 1.50-1.96, P < 0.001] and disease control rate [RR = 1.30, 95% CI 1.19-1.43, P < 0.0001], longer survival [HR = 0.48, 95% CI 0.37-0.63, P = 0.0005], but an 8.96-fold increase in postoperative complications [RR = 8.96, 95% CI 4.75-16.92, P < 0.0001]. There was no significant difference in the incidence of adverse reactions between the two groups [RR = 1.02, 95% CI 0.91-1.14, P = 0.73].
conclusionsThe CT-guided 125I particle implantation therapy is able to significantly improve the short-term efficacy and survival of elderly patients with lung cancer. Although the risk of complications was significantly increased, none of the included studies reported serious complications. Our meta-analysis exhibited clinical heterogeneity due to non-uniform interventions, varied treatment protocols, inconsistent staging criteria, and study limitations such as small samples, few studies and short follow-up, potentially introducing bias. More high-quality research is needed to further validate the conclusions of this study. CLINICAL TRIAL NUMBER: This study has been registered on the PROSPERO platform (Registration number: CRD420251078821).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.